See Stories from Region:
Filter by Date:
  • close  
  • close  

GlycoMimetics to Present First Preclinical Data on E-selectin-CXCR4 Dual Antagonist for Cancer Indications at AACR Annual Meeting 2015

(Business Wire GlycoMimetics, Inc. (NASDAQ: GLYC) announced today that new preclinical research on tumor growth and metastases and the potential value of its newest drug candidate, GMI-1359, will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2015 in Philadelphia. Two posters will summarize research data on GMI-1359, a dual acting antagonist of both E-selectin and CXCR4, demonstrating its anti-tumor activity both alone and in combination with chemotherapy in preclinical models of pancreatic and prostate tumor growth. A third poster reports on preclinical studies where GMI-1271, an E-selectin specific antagonist, demonstrates complimentary yet differing roles of E-selectin and CXCR4 in breast cancer metastasis to bone. The AACR Annual Meeting 2015 takes place from April 18 to 22, 2015, at the Pennsylvania Convention Center.

“Our initial data supports further evaluation of our E-selectin-CXCR4 antagonist and its potential role in addressing a variety of cancers, including those giving rise to bone metastases,” said John Magnani, Ph.D., GlycoMimetics Vice President and Chief Scientific Officer. “We are pleased to have an opportunity to share our pre-clinical data with the research community and plan to continue our studies of this promising drug and a novel approach to addressing some of the most difficult to treat cancers.”

The AACR posters from GlycoMimetics, including abstract title, session times, and locations, include the following:

  • “A Small Molecule Glycomimetic Antagonist of E-Selectin and CXCR4 (GMI-1359) Prevents Pancreatic Tumor Metastasis and Improves Chemotherapy” [Tumor Biology: Cytokines and Chemokines and the Microenvironment – Poster Session PO.TB06.01, Sunday, April 19, 2015, 1:00-5:00 p.m. Eastern Time] Abstract 425
  • “Dual E-selectin and CXCR4 Inhibition Reduces Tumor Growth and Increases the Sensitivity To Docetaxel in Experimental Bone Metastases of Prostate Cancer” [Tumor Biology: Cytokines and Chemokines and the Microenvironment – Poster Session PO.TB06.01, Sunday, April 19, 2015, 1:00-5:00 p.m. Eastern Time] Abstract 428
  • “Metastatic Breast Cancer Cell Communication Within a Pro-dormancy Bone Marrow Niche” [Tumor Biology: Dynamic Regulation of the Tumor Microenvironment – Poster Session PO.TB06.08, Tuesday, April 21, 2015, times 8:00-12:00 p.m. Eastern Time] Abstract #3212

About GlycoMimetics, Inc.

GlycoMimetics is a clinical stage biotechnology company focused on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role. Pfizer is the company's development partner for rivipansel, a GlycoMimetics-discovered investigational therapy for pain crisis associated with sickle cell disease, and is preparing to conduct a Phase 3 clinical study. A GlycoMimetics wholly-owned candidate therapy (GMI-1271) for acute myeloid leukemia (AML) and other blood disorders is also in clinical trials. Glycomimetics are molecules that mimic the structure of carbohydrates involved in important biological processes. Using its expertise in carbohydrate chemistry and knowledge of carbohydrate biology, GlycoMimetics is developing a pipeline of glycomimetic drug candidates that inhibit disease-related functions of carbohydrates, such as the roles they play in inflammation, cancer and infection. Learn more at

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements regarding the clinical development of GMI-1359 and of GMI-1271. Actual results may differ materially from those in these forward-looking statements. For a further description of the risks associated with these statements, as well as other risks facing GlycoMimetics, please see the risk factors described in the Company’s quarterly report on Form 10-K that was filed with the U.S. Securities and Exchange Commission on March 16, 2015, and other filings the Company makes with the SEC from time to time. Forward-looking statements speak only as of the date of this release, and GlycoMimetics undertakes no obligation to update or revise these statements, except as may be required by law.